Zosano Pharma — Investor Presentation (April 2016)
49 slides from Zosano Pharma's investor presentation, Apr 7, 2016
Slide 1: Corporate Presentation April 2016
ZosanoPhnarma Corporate Presentation April 2016
Slide 2: Forward-looking statement
forward-looking statement This presentation contains forward‐looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding our commercialization, our research and other development programs, our ability to undertake certain
Slide 3: Zosano Pharma (NASDAQ:ZSAN) – investment highlights
zosano pharma (NASDAQ:ZSAN) – investment highlights Differentiated transdermal microneedle ZP-Patch delivery platform Fast onset with short Tmax: oral takes 3x longer to Cmax1 (injection-comparable) Convenient and easy-to-use: room temperature stable, portable Technology clinically validated ZP-PTH
Slide 4: ZP-Triptan: potential for fast relief in migraine episodes
zp-triptan: potential for fast relief in migraine episodes Potential for rapid onset of pain relief Compound with known efficacy / safety profile Transdermal delivery possibly suited for multiple segments Morning migraines, migraines with nausea / vomiting symptoms, late treatment migraines Phase 1
Slide 5: Zosano Pharma drug delivery system and intellectual property
QUARTER-SIZED DELIVERY SYSTEM WITH TITANIUM, DRUG-COATED ARRAY PRESS-AND-APPLY HAND-HELD APPLICATOR FOR CONSISTENT DELIVERY INTELLECTUAL PROPERTY UNTIL 2027 (Issued Patents (owned & licensed) = 25 US, 14 EU, 15 JP)1 zosano pharma drug delivery system Transdermal & PTH Formulation/ Coating/PK/PD 8 US
Slide 6: Zosano Pharma clinical pipeline
zosano pharma clinical pipeline Daily ZP-PTH Preclinical Phase 1 Phase 2 Phase 3 ZP-Triptan ZP-Glucagon WW Commercial Rights Target Indication Migraine Osteoporosis Severe Hypoglycemia Pivotal Efficacy Data Expected by Q1:17
Slide 7: Management team / financial highlights
management team / financial highlights Name Title Experience Konstantinos Alataris, PhD Chief Executive Officer Donald Kellerman, PharmD VP, Clinical Development & Medical Affairs Hayley Lewis, RAC VP, Regulatory Affairs & Quality Assurance Winnie Tso, CPA Chief Financial Officer Eric Scharin VP, En
Slide 8: Migraine Overview
Migraine Overview
Slide 9: Migraine headaches
migraine headaches Migraine is a common and disabling form of headache with approximately 30 million patients in U.S. suffering from migraines annually1,2 Migraine is a chronic disease with recurrent episodes2 Migraine episodes can last from several hours to days3 Migraine is characterized by throbb
Slide 10: Fast pain relief ranked as critical by migraine patients
fast pain relief ranked as critical by migraine patients Attributes of acute migraine treatments rated as important by migraineurs in the general population1 Migraineurs (%) Reporting Each Attribute Adapted from Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with
Slide 11: Need for fast pain relief persists
need for fast pain relief persists Sources: IMITREX® FDA label (25 mg dose), Fox AW. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache. 2004;44:142-147, FDA prescribing information, Zomig Oral FDA Label , Adelman et al., Comparative Aspects of Triptans in Treat
Slide 12: Faster absorption (Tmax) correlates with faster onset of pain relief
Faster absorption (Tmax) correlate with faster onset of pain relief Sources: IMITREX® FDA label (25 mg dose), Fox AW. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache. 2004;44:142-147, FDA prescribing information, Zomig Oral FDA Label , Adelman et al., Compara
Slide 13: Zosano's Solution: ZP-Triptan
Zosano’s Solution: ZP-Triptan
Slide 14: Zosano Pharma drug delivery system: rapid onset and high bioavailability
zosano pharma drug delivery system rapid onset and high bioavailability Patch consists of a 3 cm2 array of titanium microneedles attached to adhesive patch Proprietary formulation of triptan coated onto the microneedles Quickly dissolved resulting in short Tmax Drug Coated Patch
Slide 15: ZP-Triptan preclinical data demonstrated high bioavailability with rapid onset
zp-triptan preclinical data demonstrated high bioavailability with rapid onset PK Parameters IV ZP Zolmitriptan Zolmitriptan Coated Dose (mg) N/A 1.9 mg 3.8 mg Zolmitriptan Dose (mg/kg) 0.075 0.058 0.165 Cmax (ng/mL) 251.7 ± 34.1 8.4 ± 3.7 24.3 ± 6.7 Median Tmax (min) 1 15 (10-30) 5 (5-15) AUC(0-t)
Slide 16: ZP-Triptan Phase 1 data
zp-triptan phase 1 data Plasma Concentration (All Treatment Groups) 0-2 hrs Rapid Tmax, oral takes 3x longer to Cmax, dose-linear PK and well tolerated ZP-Triptan Median Tmax Oral Zolmitriptan Median Tmax
Slide 17: ZP-Triptan target migraine segments
zp-triptan target migraine segments Foley et al., Headache, 2005;45:538-545;National Headache Foundation; US Headache Consortium Pocket Guide; http://eguideline.guidelinecentral.com/i/76857. Silberstein S., Headache. 1995 Jul-Aug;35(7):387-96.
Slide 18: ZP-Triptan development milestones
zp-triptan development milestones Pivotal efficacy completion by Q1 2017 Long term safety completion by Q2 2018 NDA Submission by Q3 2018 Estimated cost to NDA: $25-30 MM
Slide 19: Pivotal efficacy study design
pivotal efficacy study design Single Efficacy Study Required Subjects: 360 Population: Migraine 2-8/month Design: Each migraine sufferer will take a single dose to treat a qualifying migraine Sites: 35 Centers in U.S. Doses: ZP-Triptan 1, 1.9, and 3.8 mg, Placebo Primary Endpoint: Proportion of subj
Slide 20: Safety study design
safety study design Migraine Safety Study Subjects: 250 enrolled to achieve 150 at 6 months and 50 at 12 months Population: Subjects with historically 2-8 migraines/month Design: Open-Label, visits at 1,3, 6, 9, and 12 months to record adverse events Sites: 20 Dose: The commercial dose (To be determ
Slide 21: ZP-Triptan Market Potential
ZP-Triptan Market Potential
Slide 22: Migraine market: triptans are the most prescribed migraine-specific medication
migraine market triptans are the most prescribed migraine-specific medication Undiagnosed: 12.2 MM Only OTC or Other Rx: 4.9 MM Migraine Prevalence (US): 30.8 MM1 60% Diagnosed: 18.6 MM1 Treated: 13.7 MM1 74% Decision Resources (Number of Total, Diagnosed, and Acutely Drug-Treated Prevalent Cases of
Slide 23: Migraine market projected to grow 8% year-over-year over next five years
migraine market projected to grow 8% year-over-year in revenue over next five years MIGRAINE MARKET BY PRODUCT1 MIGRAINE MARKET BY CLASS1 Evaluate, Ltd. Triptan products represented approximately 63% of the migraine market in 20141
Slide 24: Competition – pipeline programs
competition – pipeline programs Product Administration Phase 1 Phase 2 Phase 3 Prelaunch/ Launch Onzetra Xsail (sumatriptan) Nasal Powder COL-144 (lasmiditan) Oral Tablet ALD403 (anti-CGRP) Intravenous LY2951742 (anti-CGRP) Subcutaneous AMG 334 (anti-CGRP) Subcutaneous Rizaport ODF (rizatriptan) Ora
Slide 25: Gastric stasis is a complicating factor in migraine
gastric stasis (slows absorption of oral agents) is a complicating factor in migraine Gastric stasis has been associated with migraine1,3 Gastric stasis may delay absorption of oral medications used for the treatment of migraine and negatively impact treatment efficacy1,2,3 Time to Half Emptying of
Slide 26: ZP-Triptan potential differentiation over alternative treatment options
zp-triptan potential differentiation over alternative treatment options CHALLENGES WITH CURRENT TREATMENT OPTIONS : Slow onset of action Inconsistent response due to gastric stasis Unpleasant to taste1 Limited utility when taken late in migraine Limited utility in presence of nausea / vomiting Cause
Slide 27: Market potential for ZP-Triptan
market potential for zp-triptan Diagnosed Patients1 ~19 MM Patients Requiring Non-Oral Therapy2 1.9 MM Migraines per Pt per Year1 33 Migraine Episodes for Non-Oral 62 MM Diagnosed Patients1 ~19 MM Migraines per Pt per Year1 33 % Morning Migraine Episodes (4am - 9am)3 48% Morning Migraine Episodes 30
Slide 28: Appendix
Appendix
Slide 29: ZP-Glucagon
ZP-Glucagon
Slide 30: ZP-Glucagon: potential to expand highly underserved market
zp-glucagon: potential to expand highly underserved market Severe hypoglycemia is life-threatening, requiring emergency rescue Ease-of-use critical for third-party caregivers who may lack medical training Rapid onset important for fast recovery Underpenetrated market generates ~$220 million in WW sa
Slide 31: Zosano solution vs currently marketed glucagon product
Complex, multi-step reconstitution, third party administered Significant prep time Press-and-Apply pre-loaded disposable system Fast, simple, no prep needed Unstable formulation Stable, dry patch formulation Short shelf life after reconstitution No reconstitution required current products not user-f
Slide 32: Phase 2 clinical trial summary: diabetic subjects with insulin-induced hypoglycemia
phase 2 clinical trial summary: diabetic subjects with insulin-induced hypoglycemia Objective: evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic (glucose) of a single treatment of ZP-Glucagon patches at doses of up to 1 mg compared to IM injection in an insulin-induced hypoglyc
Slide 33: Glucagon promotes rapid glucose response (full time course)
glucagon promotes rapid glucose response (full time course) Glucagon PK Curve Glucagon AUC Glucagon Tmax Glucose Change from Baseline FASTER PATCH TMAX VS. IM INJECTION ZP-Glucagon 0.5 MG ZP-Glucagon 1.0 MG Glucagon IM 0.5 MG Glucagon IM 1.0 MG 0.5 MG OF GLUCAGON IS ABOVE DOSE-RESPONSE CURVE, EVEN W
Slide 34: Glucagon promotes rapid glucose response (first minutes)
glucagon promotes rapid glucose response (first 30 minutes time course) Glucagon PK Curve Glucagon AUC Glucose Change from Baseline ZP-Glucagon 0.5 MG ZP-Glucagon 1.0 MG Glucagon IM 0.5 MG Glucagon IM 1.0 MG Glucagon Tmax 100% RESPONDER RATE 0.5 MG PATCH ACHIEVES COMPARABLE AUC TO 1.0 MG IM
Slide 35: Phase 2 findings
phase 2 findings Both ZP-Glucagon patch doses normalized blood sugar in 100 percent of the subjects (100% responder rate) Both patch doses achieved rapid onset of action Time to glucose response was similar when comparing ZP-Glucagon patch to IM All treatments were well tolerated and no new safety i
Slide 36: Formulation stability a significant competitive advantage
formulation stability a significant competitive advantage
Slide 37: Phase 1 clinical trial design: robust crossover design in healthy volunteers
phase 1 clinical trial design: robust crossover design in healthy volunteers Objective: evaluate safety, tolerability, PK and PD of ZP-Glucagon patch doses of 0.5 mg compared to IM injection of 0.5 mg Design: single-center, open-label, randomized five-way crossover study Testing Regimens: 0.5 mg of
Slide 38: Phase 1 PK data vs. injection
phase 1 pk data vs. injection: short tmax, high bioavailability and low variability across doses 20 subjects tested in five-way crossover study pg/ml A: Patch formulation C / abdomen B: Patch formulation C / forearm C: Patch formulation C / upper arm D: Patch formulation D / abdomen E: Glucagon IM i
Slide 39: Phase 1 glucose data vs. injection
phase 1 glucose data vs. injection: all patch doses with comparable pd to injection mmol/l A: Patch formulation C / abdomen B: Patch formulation C / forearm C: Patch formulation C / upper arm D: Patch formulation D / abdomen E: Glucagon IM injection
Slide 40: ZP-PTH
ZP-PTH
Slide 41: Daily ZP-PTH patch program: Phase 2 trial design
daily zp-pth patch program: phase 2 trial design 6 month multi-national trial completed in 2008 165 post-menopausal women with low bone density Daily dose, patient self-administered ZP-PTH patch at 3 doses (20 µg, 30 µg and 40 µg) ZP-Placebo patch as control Forteo® injection product (20 µg) as acti
Slide 42: Phase 2 results - PK profile: pulsatile delivery critical for anabolics
Phase 2 results - pk profile: pulsatile delivery critical for anabolics Achieved dose proportionate and pulsatile pharmacokinetics Variability in patch doses comparable to Forteo injectable PK over time Mean auc by dose HOURS
Slide 43: Phase 2 results: bone mineral density endpoints
PHASE 2 RESULTS HIP BMD SPINE BMD ZP-PTH 20µg ZP-PTH 30µg ZP-PTH 40µg FORTEO 20µg Placebo Placebo ZP-PTH 20µg ZP-PTH 30µg ZP-PTH 40µg FORTEO 20µg bone mineral density (bmd) endpoints: higher hip bmd gains vs. forteo Ref: Cosman et al JCEM, 2010
Slide 44: Daily ZP-PTH – potential product development
daily zp-pth – potential product development Agreement for Phase 3 trial design reached with FDA / European agencies Single pivotal trial instead of multiple trials Phase 3 design would be expected to be larger and longer version of successful Phase 2 in U.S. Non-inferiority BMD gains study vs. Fort
Slide 45: ZP-Triptan
ZP-Triptan
Slide 46: Market pricing of non-oral formulations
Market pricing of non-oral formulations Dose Assumptions: Recommended single dose per attack: Alsuma= 6mg inj; Zomig Nasal Spray= 5mg spray; Sumavel= 6mg inj; Imitrex Nasal Spray = 5mg; Zecuity= 1 transdermal patch (6.5mg) Redbook (accessed 3/30/15); FDA Product Labels Evlauate, Ltd. Cost Per Attack
Slide 47: Migraine symptoms
migraine symptoms Migraine Symptoms at Screening in 2,396 Patients with Migraine1 % of Patients Schreiber CP et al., Prevalence of Migraine in Patients With a History of Self-Reported or Physician Diagnosed Sinus Headache . Arch Intern Med. 2004;164:1769-1772. 24% 28% 57% 67% 73% 79% 85% 89% 97% 0%
Slide 48: Migraine profile
migraine profile An Estimated 30 Million People in the US Have Migraine Headaches1 n=19,968 1-Year Period Prevalence2 National Headache Foundation; www.headaches.org/press/NHF_Press_Kits_-_Categories_Of_Headache. Lipton RB et al., Migraine Prevalence, Disease Burden, and the Need for Preventive Ther
Slide 49: ZP-Triptan Phase 1 data
| ZP-TRIPTAN PHASE 1 DATA | Cmax (SD) — Tmax (range) AUCo.2n (SD) ~AUCo ast (SD) ng/ml minutes ng/ml hour ng/ml hour ZP-Triptan 0.48 mg 1.8(0.53) 20(2-30) 2.1 (0.73) 2.8 (1.36) ZP-Triptan 2 x 0.48 mg 3.7 (1.05) 20(2-30) 4.2 (0.95) 6.5 (1.97) Z-Triptan 1.9 mg 6.8(2.75) 20(2-30) —7.4 (2.53) 12.3 (4.31